? COMPARATIVE PATHOLOGY & DIGITAL IMAGING SHARED RESOURCE (CPDISR) The CPDISR provides expert, readily available and affordable experimental pathology support to investigators conducting research for understanding the development and treatment of cancer using preclinical animal models and/or human tissues procured for translational research. During the current funding period, a recent major development was the inclusion of complete histology services optimized for human tissues, as well as expanded slide digitization and quantitative image analysis services for stained human and animal tissue slides. As a result, Dr. Anil Parwani (MCC) has been named co-Director with Dr. Krista La Perle (CB), the name of the shared resource (SR) has been changed to the Comparative Pathology & Digital Imaging Shared Resource, and the Specific Aims have been modified accordingly.
The Specific Aims are to: 1) provide consultative services to OSUCCC investigators for optimal experimental design, sample submission and data analysis, and interactions with other SRs; 2) provide support for preclinical efficacy and toxicity animal studies as well as translational studies that utilize human tissues; and 3) perform digitization and quantitative image analysis of stained slides from animal and human tissues. During the current 5-year grant cycle, a third board certified veterinary pathologist and seven additional technical staff have been added to anticipate usage in conjunction with the robust OSUCCC recruitment and strategic priorities. The CPDISR also acquired a Leica PELORIS 3 dual retort tissue processor after successful peer-reviewed funding through the OSUCCC Intramural Research Program. During this grant cycle, the CPDISR contributed to 84 publications (12 > 10 impact factor), 537 investigators, and 57 NCI grants, including 1 K12, 1 K22, 1 K24, 5 P01s, 1 P50, 35 R01s, 7 R21s, 2 R35s, 1 T32, and 3 U01s involving members of all five OSUCCC research programs. For the next grant cycle, the CPDISR will be a regular member of the Immune Monitoring and Discovery Platform, an overarching shared resource initiative fostering complex immuno-oncology projects. In addition, a major emphasis will be to continue to expand our available menu of antibodies optimized for immunohistochemistry, immunofluorescence and in situ hybridization in tissues of animal and human origin by various staining platforms, including multiplexing, according to the specific needs of OSUCCC members. We will also increase our support of image analysis projects allowing machine learning approaches to be developed with the center for cancer engineering; and continue to evaluate available open source and commercial image analysis software platforms/modules to complement our Aperio and Visiopharm software in order to quantify biomarkers in animal and human tissues. The annual budget of the CPDISR is $1,863,254, yet the CCSG request is $107,366. As such, the CPDIR seeks only 5.8% budgetary support from CCSG funds.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016058-45
Application #
10090009
Study Section
Subcommittee H - Clinical Groups (NCI)
Project Start
1997-09-12
Project End
2025-11-30
Budget Start
2020-12-01
Budget End
2021-11-30
Support Year
45
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Ohio State University
Department
Type
DUNS #
832127323
City
Columbus
State
OH
Country
United States
Zip Code
43210
Fu, Xinping; Tao, Lihua; Wang, Pin-Yi et al. (2018) Comparison of infectivity and spread between HSV-1 and HSV-2 based oncolytic viruses on tumor cells with different receptor expression profiles. Oncotarget 9:21348-21358
Brewington, Beatrice Y; Shao, Yusra F; Davidorf, Fredrick H et al. (2018) Brachytherapy for patients with uveal melanoma: historical perspectives and future treatment directions. Clin Ophthalmol 12:925-934
Doogan, Nathan J; Cooper, Sarah; Quisenberry, Amanda J et al. (2018) The role of travel distance and price promotions in tobacco product purchase quantity. Health Place 51:151-157
Byrd, John C; Ruppert, Amy S; Heerema, Nyla A et al. (2018) Lenalidomide consolidation benefits patients with CLL receiving chemoimmunotherapy: results for CALGB 10404 (Alliance). Blood Adv 2:1705-1718
Oblinger, Janet L; Burns, Sarah S; Huang, Jie et al. (2018) Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation. Exp Neurol 299:299-307
Shu, Yi; Yin, Hongran; Rajabi, Mehdi et al. (2018) RNA-based micelles: A novel platform for paclitaxel loading and delivery. J Control Release 276:17-29
Scoville, Steven D; Nalin, Ansel P; Chen, Luxi et al. (2018) Human AML activates the aryl hydrocarbon receptor pathway to impair NK cell development and function. Blood 132:1792-1804
McMillan, Elizabeth A; Ryu, Myung-Jeom; Diep, Caroline H et al. (2018) Chemistry-First Approach for Nomination of Personalized Treatment in Lung Cancer. Cell 173:864-878.e29
Schimizzi, Gregory V; Jin, Linda X; Davidson 4th, Jesse T et al. (2018) Outcomes after vascular resection during curative-intent resection for hilar cholangiocarcinoma: a multi-institution study from the US extrahepatic biliary malignancy consortium. HPB (Oxford) 20:332-339
Wang, Yufeng; Dong, Wenjuan; Zhang, Yibo et al. (2018) Dependence of innate lymphoid cell 1 development on NKp46. PLoS Biol 16:e2004867

Showing the most recent 10 out of 2602 publications